Scilex Holding Company (SCLX)
Healthcare
Drug Manufacturers - General
6.60 $
+0.3%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Scilex Holding Company (SCLX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 73.7% of the shares are freely tradable; institutional investors hold 13.1%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
13.1%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
17.6%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
73.7%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
3.7%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
7Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Armistice Capital, LLC | 4.23 | 297,706 | -37.5 | 03/31/2026 |
| Vanguard Group Inc | 4.19 | 295,024 | +4.5 | 12/31/2025 |
| Vanguard Capital Management, LLC | 3.75 | 264,050 | +0.0 | 03/31/2026 |
| BlackRock Inc | 1.46 | 102,796 | +4.5 | 03/31/2026 |
| Vanguard Fiduciary Trust Co | 0.56 | 39,658 | +0.0 | 03/31/2026 |
| Renaissance Technologies Corp | 0.52 | 36,864 | -4.2 | 03/31/2026 |
| State Street Corp | 0.50 | 35,376 | +3.0 | 03/31/2026 |
| XTX Topco Ltd | 0.32 | 22,606 | +10.6 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 2.51 | 176,617 | +0.0 | 04/30/2026 |
| Vanguard Institutional Extnd Mkt Idx Tr | 1.09 | 76,511 | +0.0 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.